Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

No Difference in Baraclude Versus Baraclude Plus Tenofovir

November 8, 2011 11:30 am | News | Comments

Bristol-Myers Squibb announced results from the Be?Low study, a Phase 3b clinical trial comparing Baraclude monotherapy with Baraclude plus tenofovir in treatment-naïve adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease.

Neovacs Releases Lupus Study Results

November 8, 2011 11:26 am | News | Comments

Neovacs announced the results of its IFN-K-001 clinical study in lupus that showed that Kinoid treatment reduces the gene dysregulation associated with the overexpression of IFN?.

EV-077 Receives Clearance for Phase 2a Trial

November 8, 2011 11:22 am | News | Comments

Evolva has received regulatory clearance to progress its pharmaceutical compound EV-077 into Phase 2a clinical studies for the treatment of complications of diabetes.


Ciclesonide Nasal Aerosol Shows Positive Results

November 8, 2011 11:19 am | News | Comments

Sunovion Pharmaceuticals Inc. announced results from a Phase 3 clinical study of ciclesonide nasal aerosol, intended for the treatment of allergic rhinitis.

Researchers Uncover Foldit Gamers’ Strategies

November 8, 2011 11:16 am | News | Comments

Researchers studying the nature of crowds playing Foldit called some strategies “shocking” in how well they mimicked some of the methods already used by protein scientists.

Heptares Expands Management Team

November 8, 2011 11:13 am | News | Comments

Heptares Therapeutics has appointed Daniel Grau to president.


Stem-cell Growth Triples in Culture

November 8, 2011 11:10 am | News | Comments

By irradiating polystyrene lab plates with ultraviolet waves, Whitehead Institute and Massachusetts Institute of Technology scientists have created a surface capable of tripling the number of human embryonic stem and induced pluripotent stem cells that can be grown in culture by current methods.

Pipette Tips

November 8, 2011 11:04 am | Product Releases | Comments

Beckman Coulter Inc. offers Biomek P1000 Span-8 pipette tips for the Biomek NXP and FXP laboratory automation workstations, which allow users to inspect aspirated volumes.


Solvent-Resistant Labels

November 8, 2011 11:02 am | Drug Discovery & Development, Drug Discovery & Development | Product Releases | Comments

CILS International’s CILS-8200S solvent-resistant surface coating ensures variable data remains clear and legible when exposed to methanol, ethanol, acetone, IPA and THF.

Ductless Fume Hoods

November 8, 2011 10:59 am | Product Releases | Comments

The Purair 5 Ductless Fume Hoods from Air Science USA are available in 24 in, 36 in or 48 in models.

Cell Culture Roller Bottles

November 8, 2011 10:58 am | Drug Discovery & Development, Drug Discovery & Development | Product Releases | Comments

Thermo Fisher Scientific Inc.’s Nunc Roller Bottles are designed for cell culture applications in the production of vaccines and monoclonal antibody-based biopharmaceuticals.

Syringe Filter

November 8, 2011 7:06 am | Drug Discovery & Development | Product Releases | Comments

Pall Corporation introduced the Pall Acrodisc MS Syringe Filter the first syringe filter certified for low extractables in high-performance liquid chromatography/mass spectrometry applications.


Preparative Ultracentrifuges

November 8, 2011 6:28 am | Product Releases | Comments

The Optima X Series preparative ultracentrifuges from Beckman Coulter, Inc. incorporate an array of contemporary technical features to enhance the user experience, increase productivity, and reduce costs.


LEO Pharma Installs CM3

November 8, 2011 6:18 am | News | Comments

Freeslate, Inc. announced that LEO Pharma has selected Freeslate’s Core Module 3 high-throughput research platform for evaluating solubility of drugs in various viscous formulations and for preparing samples for characterization and analysis.


MAP Pharma Earns $11M in Q3

November 8, 2011 6:09 am | News | Comments

MAP Pharmaceuticals Inc. said that it made a profit in the third quarter after receiving two payments from its partner, Allergan Inc. MAP said it earned $11.2 million, or 35 cents per share, and it reported $23.9 million in revenue.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.